- Home
- BRID vs ANVS Comparison
BRID vs ANVS Comparison
Compare BRID & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRID
- ANVS
- Stock Information
- Founded
- BRID 1932
- ANVS 2008
- Country
- BRID United States
- ANVS United States
- Employees
- BRID N/A
- ANVS N/A
- Industry
- BRID Specialty Foods
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- BRID Consumer Staples
- ANVS Health Care
- Exchange
- BRID Nasdaq
- ANVS Nasdaq
- Market Cap
- BRID 70.3M
- ANVS 54.6M
- IPO Year
- BRID N/A
- ANVS 2020
- Fundamental
- Price
- BRID $7.80
- ANVS $2.18
- Analyst Decision
- BRID
- ANVS Strong Buy
- Analyst Count
- BRID 0
- ANVS 5
- Target Price
- BRID N/A
- ANVS $30.25
- AVG Volume (30 Days)
- BRID 5.9K
- ANVS 616.9K
- Earning Date
- BRID 08-22-2025
- ANVS 08-14-2025
- Dividend Yield
- BRID N/A
- ANVS N/A
- EPS Growth
- BRID N/A
- ANVS N/A
- EPS
- BRID N/A
- ANVS N/A
- Revenue
- BRID $224,673,000.00
- ANVS N/A
- Revenue This Year
- BRID N/A
- ANVS N/A
- Revenue Next Year
- BRID N/A
- ANVS N/A
- P/E Ratio
- BRID N/A
- ANVS N/A
- Revenue Growth
- BRID N/A
- ANVS N/A
- 52 Week Low
- BRID $7.50
- ANVS $1.11
- 52 Week High
- BRID $14.69
- ANVS $17.88
- Technical
- Relative Strength Index (RSI)
- BRID 46.14
- ANVS 43.14
- Support Level
- BRID $7.64
- ANVS $2.52
- Resistance Level
- BRID $8.71
- ANVS $3.18
- Average True Range (ATR)
- BRID 0.28
- ANVS 0.31
- MACD
- BRID 0.02
- ANVS -0.10
- Stochastic Oscillator
- BRID 24.19
- ANVS 5.38
About BRID Bridgford Foods Corporation
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.